33 results about "Ribosomal protein" patented technology

The invention belongs to the technical field of biological diagnosis, and particularly relates to application of a reagent for detecting DNA methylation of an RPL10 promoter region in preparation of a sow pregnancy diagnosis product. Through methylation high-throughput sequencing of blood DNA of pregnant sows and non-pregnant sows, it is found that the methylation level of a gene promoter region of the ribosomal protein L10 in the early pregnancy stage of the sows is remarkably reduced. The methylation level of the pregnant sow RPL10 is analyzed by using MSP, BSP and qMSP methods, and meanwhile, the ROC curve analysis result also shows that the RPL10 has diagnostic value. The results show that the method for detecting the RPL10 gene in the pig blood sample can be an effective method for diagnosing the early pregnancy of pigs. According to the invention, a pregnancy diagnosis technology based on RPL10 promoter region DNA methylation is preliminarily established, pig pregnancy detection methods are enriched, and a reference is provided for further exploring the DNA methylation level and the regulation mechanism of the pig pregnancy early stage.

The invention relates to pichia pastoris for producing brazitame protein as well as a construction method and application of the pichia pastoris, and belongs to the technical field of microorganisms. ExpL SP is used as a signal peptide in pichia pastoris, heterologous expression of Brazilian sweet protein is carried out through an AOX1 promoter, the ExpL SP and a Pro region of an alpha mating factor are further fused and transformed to obtain a new signal peptide to enhance the secretion efficiency, and the new signal peptide and a ribosomal protein synthesis factor Bcy1 are co-expressed to improve the protein synthesis capacity. The constructed pichia pastoris can be used for efficiently secreting the Brazilian sweet protein, the problems that in the prior art, when microorganisms are used for fermenting the Brazilian sweet protein, the Brazilian sweet protein is mistakenly folded, the sweet taste is reduced or lost are solved, the shake flask yield is stabilized at 450 mg / L, the fermentation tank yield reaches 5.215 g / L, and a high-cost-performance scheme is provided for industrial production of the Brazilian sweet protein.

The invention relates to an application of zebrafish 80S ribosomal protein 7oyb in influence on inhibition of zebrafish embryo fibroblast proliferation by DON, and belongs to the technical field of molecular biology, the application is characterized in that the binding of vomitoxin and zebrafish ribosomal protein 7oyb is interfered by influencing the binding site of the vomitoxin on the zebrafish 80S ribosomal protein 7oyb, so that the zebrafish embryo fibroblast proliferation is inhibited, and the zebrafish embryo fibroblast proliferation is inhibited. The specific combination is as follows: the vomitoxin forms hydrogen bonds with nucleotides G17192, C17202 and C17312 on the 18s RNA, and forms hydrophobic interaction with PRO90 and HIS92 of G15932 and 40S ribosomal protein S19 on the 18s RNA; the invention also provides application of vomitoxin in inhibition of zebrafish embryo fibroblast proliferation. According to the application disclosed by the invention, acting sites of the DON in inhibition of zebrafish embryo fibroblast proliferation are found for the first time, and the problem that the DON inhibits the zebrafish embryo fibroblast proliferation can be solved by interfering the combination of the sites and the DON.

Provided is a method of identifying a serovar of Salmonella bacteria including a step of subjecting a sample containing microorganisms to mass spectrometry to obtain a mass spectrum, a step of reading a mass-to-charge ratio m / z of a peak derived from a marker protein from the mass spectrum, and an identification step of identifying a serovar of Salmonella bacteria in the sample, based on the mass-to-charge ratio m / z, wherein the serovars of Salmonella bacteria are classified using cluster analysis using as an index the mass-to-charge ratio m / z derived from at least 12 types of ribosomal proteins S8, L15, L17, L21, L25, S7, SODa, peptidylprolyl isomerase, gns, YibT, YaiA and YciF as the marker proteins.

The invention provides application of a paeoniflorin photoaffinity probe in screening key target protein of paeoniflorin, and relates to the technical field of chemical proteomics. The paeoniflorin photoaffinity probe has a structure as shown in a formula I, and the paeoniflorin key target proteins are 40S ribosomal protein S3 and statin 2. The paeoniflorin photoaffinity probe is applied to screening of the paeoniflorin key target proteins, so that two target proteins combined with paeoniflorin in liver cells are successfully identified; the two target proteins are respectively 40S ribosomal protein S3 (RPS3) and statin 2 (PHB2), and the two target proteins participate in the protection effect of paeoniflorin on the liver, and have the key effects of oxidation resistance, inflammation resistance, immunoregulation and the like in liver diseases.

The present disclosure provides methods for inducing cellular quiescence—defined as a reversible arrest of cell proliferation—by inhibiting ribosome biogenesis. The methods involve administering a quiescence-inducing agent, such as a small molecule inhibitor, peptide, antisense oligonucleotide, or targeted degrader, that interferes with rRNA transcription, processing, ribosomal protein synthesis, or ribosome assembly. The agent may be applied to cultured cells, tissues, organs, or organoids, across a range of cell types and species. In some embodiments, the methods reduce metabolic activity and enhance stress resistance in non-dividing or post-mitotic cells. By slowing proliferation and / or metabolism while preserving viability, these methods enable improved preservation of cells, tissues, and organs-enhancing transplantation logistics, biobanking, regenerative medicine workflows, and biological transport. Additional applications include studies of cell cycle regulation, tissue regeneration, stress biology, aging, and induction of organismal hypometabolism (e.g., torpor or hibernation). The disclosure includes examples demonstrating quiescence induction using chemical biology systems, pharmacological agents, and genetic approaches.

This invention provides an expression cassette, an expression vector, a genetically engineered strain, and their application in the preparation of malonic acid. The expression cassette includes expression cassette 1, expression cassette 2, and expression cassette 3. Expression cassette 1 includes the gene for the mitochondrial 37S ribosomal protein mS47; expression cassette 2 includes the ACC1 gene, which incorporates a mitochondrial localization signal encoding gene at its 5' end; and expression cassette 3 includes the upstream homologous arm of an endogenous ACC1 gene, which incorporates a weak promoter at its 5' end. This invention, through the expression cassette, can promote an increase in the levels of mS47 and ACC1 in mitochondria, thereby promoting the synthesis pathway of acetyl-CoA-malonyl-CoA-malonic acid (ACEA), while simultaneously reducing the level of endogenous ACC1 in the cytoplasm, avoiding competitive effects on the mitochondrial ACEA synthesis pathway, and ultimately effectively increasing malonic acid production.

The application discloses a natural fissistilarin component derivative DhpB and application thereof, and particularly application thereof as a covalent binding ubiquitinase MKRN2 target in anti-KRAS mutant lung cancer. The derivative is from a plant of Peperomia in Piperaceae, can significantly inhibit in-vivo and in-vitro proliferation of KRAS mutant non-small cell lung cancer cells, and induce tumor cell apoptosis through semi-synthetic structure optimization. DhpB is covalently combined with ubiquitinase MKRN2 abnormally expressed in KRAS mutant lung cancer cells, promotes combination of MKRN2 and small ribosomal protein RPS7, thereby promoting ubiquitination and degradation of RPS7, and causes ribosome stress-induced apoptosis of tumor cells. The application provides a new target and inhibitor for preparing a drug for treating refractory KRAS mutant lung cancer, and has a good medicinal prospect.

The invention provides a marker for detecting quality deterioration of stored millet. The marker is 60S ribosomal protein L18a and / or 40S ribosomal protein S4. The marker provided by the invention can be used for accurately and conveniently detecting the quality deterioration condition of the stored millet, and is of great significance to food safety and production of grain enterprises.

The invention belongs to the technical field of gene engineering, and particularly relates to a ribosomal protein N'mutant and application thereof. The ribosomal protein N'mutant is subjected to Y190D mutation, and after the ribosomal protein N 'expressed by a production strain is subjected to Y190D mutation, the yield of LNT II is increased by 28.6%, the yield of LNnT is increased by 50%, the yield of LNT is increased by 92.3%, the yield of 3'-SL is increased by 13.8%, and the yield of 6 '-SL is increased by 20%. Therefore, after the 190th amino acid of the PriA is changed from tyrosine to aspartic acid, the production capacity of the PriA is improved, and when the PriA is applied to escherichia coli for producing the human milk oligosaccharide, the yield of the human milk oligosaccharide is remarkably improved finally.

The invention relates to the technical field of insect molecular biology, and particularly provides a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) reference gene of small blue-and-white chamaecyparis and application thereof. The method comprises the following steps: selecting seven candidate reference genes for fluorescent quantitative PCR (Polymerase Chain Reaction) analysis by taking different tissues of the small blue-and-white turtle as materials, performing gene stability evaluation on the Ct value of each candidate gene by adopting a delta Ct method, geNorm, NormFinder, BestKeeper and RefFinder, and screening to obtain the fluorescent quantitative PCR reference gene ribosomal protein S3 (RPS3) and ribosomal protein L31 (RPL31) which are stably expressed in different tissues of the small blue-and-white turtle. The reference gene is suitable for fluorescent quantitative PCR of different tissues of small blue-and-white chamaecyparis, and provides a basic support for subsequent gene function research.

Provided are methods for using chimeric proteins to produce RNA modifications that can be detected by sequencing methods, including methods detecting relative translation rates of various mRNAs. Also provided herein are compositions comprising chimeric proteins, wherein the chimeric proteins comprise a RNA editing protein and a ribosomal protein.

The invention relates to a fusion protein for preventing pathogenic enterococcus infection, an immunogenic composition, a recombinant vaccine, application of the fusion protein, the immunogenic composition and the recombinant vaccine and the like. According to the invention, HlyC / CorC transporter antigens of enterococcus faecium and enterococcus faecalis are selected to construct a fusion protein A, and elongation factor Tu antigens and 50S ribosomal protein L7 / L12 (50S ribosomal protein L7 / L12, rplL) antigens of the enterococcus faecium and the enterococcus faecalis are selected to construct a fusion protein B. According to the present invention, the fusion protein A and the fusion protein B are selected, the vaccine based on the two fusion proteins can significantly weaken tissue infection caused by enterococcus faecium and enterococcus faecalis, has good immunogenicity, plays effective prevention and immune protection roles, can efficiently prevent pathogenic enterococcus infection, and has wide application prospects.

The invention is applicable to the technical field of biology, and provides a streptococcus suis type 2 multi-epitope inhalation type subunit vaccine and application thereof. According to the invention, 4 CTL epitopes, 7 HTL epitopes and 6 B cell epitopes are screened out aiming at conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, the epitopes are fused by AAY / GPGPG / EAAAK linkers, L7 / L12 ribosomal protein is introduced as an adjuvant, and the inhalation type subunit vaccine 1022-SpaA V3 is constructed; the vaccine can improve the levels of sIgA and serum IgG of respiratory mucosa and activate related immune cells by virtue of 60 micrograms of intranasal primary immunization-enhanced immunization, so that a mucosa and system dual immune mechanism is formed; the survival rate of mice after SS2 multi-strain challenge reaches up to 100%, and the bacterial load can be reduced; and the vaccine is safe and non-toxic, is inhaled, saves cost and is suitable for industrial large-scale production.

The present invention relates to a method for identifying a pharmaceutically active compound that modulates the rpL23-dependent translation of at least one mRNA in a mammalian cell, in particular the mRNA encoding the mutated TP53 protein. The at least one mRNA may include a premature termination codon (PTC) or undergo premature translation termination. Furthermore, a screening system, methods for treating or preventing a disease or condition, such as cancer, and screened compounds or derivatives thereof are provided.

The invention provides application of Escherichia coli 50S ribosome subunit protein coding genes rmF and rplX in the aspect of improving the growth rate of prokaryotic expression bacteria, and particularly relates to an Escherichia coli 50S ribosome subunit protein L32 coding gene rmF as shown in SEQ ID NO: 2, an Escherichia coli 50S ribosome subunit protein L24 coding gene rplX as shown in SEQ ID NO: 4 and application of coding proteins of the Escherichia coli 50S ribosome subunit protein L24 coding gene rplX. It is found that after rmF and rplX genes are transferred into a prokaryotic expression strain, the growth rate of the prokaryotic expression strain under normal conditions can be increased. The engineering strain is high in growth rate and high in expression efficiency, and can be used as an important biological resource in related gene engineering.

To provide a polypeptide corresponding in sequence homology to an active region of a 40s ribosomal protein S2 ("RPS2") that is beneficial as a therapeutic for oral and iv administration.SOLUTION: Provided is an isolated polypeptide that comprises or consists of a 40s ribosomal protein S2 (RPS2) or a fragment thereof, having a specific amino acid sequence.SELECTED DRAWING: Figure 1

The invention discloses application of ribosomal proteins RPS10 and RPS27A in regulating cell growth and radiosensitivity, and belongs to the technical field of biology. In order to research the effects of specific RPs in the aspects of regulating and controlling cell proliferation, survival and radiosensitivity, peripheral blood of a human body is subjected to gamma-ray irradiation, complete transcriptome sequencing is performed on the peripheral blood before and after irradiation after irradiation, and it is found that the expression levels of various RPs genes such as RPS10, RPS27A, RPL27 and RPL35 are remarkably changed after irradiation; then, functional research is carried out on RPS10, RPS27A, RPL27 and RPL35 genes in HeLa cells, and it is found that the RPS10 and RPS27A genes have the important regulating effect on cell proliferation and survival.

The invention discloses a pretreatment reagent for mass spectrometric detection of a blood culture positive sample. Through a chemical wall-breaking mechanism, signal interference caused by cell protein in blood can be rapidly removed, bacterial cell walls can be destroyed, and ribosomal protein of microorganisms can be released. The method is suitable for direct mass spectrometric detection of blood culture positive samples, and a pathogen detection report is rapidly and accurately obtained. The key points of the technical scheme are as follows: the composition at least comprises a component A, a component B and a component C. The component A is used for destroying cell walls and cell membranes and dissolving interfering substances in blood such as blood cells and hemoglobin; the component B is an auxiliary substance for enhancing the flowability and permeability of a lipid chain on a cell membrane and assisting in releasing intracellular protein; the component C is a solvent with osmotic pressure lower than that of red blood cells. In addition, the invention also discloses a preparation method of the pretreatment reagent and a blood culture positive sample mass spectrum detection operation method based on the pretreatment reagent.

The invention belongs to the technical field of plant genetic engineering and biology, and discloses a peanut endogenous strong promoter PAhRPS5 and a preparation method and application thereof, the promoter comprises PAhRPS5A, PAhRPS5B and PAhRPS5C, and the promoter respectively corresponds to the promoter of peanut genes AhRPS5A, AhRPS5B and AhRPS5C. According to the promoter, an amino acid sequence of an arabidopsis thaliana RPS5 gene is taken as a reference, peanut RPS5 candidate genes are identified through homologous retrieval, and after high-expression genes are screened through expression quantity analysis, the promoter is obtained by cloning from a peanut Yuhua flower 9326 genome by adopting a PCR (Polymerase Chain Reaction) technology; a recombinant vector containing the promoter is constructed, peanut embryogenic calluses are transformed, and functional verification shows that the promoter can drive downstream genes to be expressed in the peanut calluses. The technical bottleneck that existing peanut gene editing depends on an exogenous promoter and is poor in adaptability is solved, the application blank of the peanut endogenous strong promoter is filled, and the peanut endogenous strong promoter can be used for constructing a peanut precise gene editing system and promoting peanut breeding improvements such as stress resistance and high quality, and has important practical value and industrialization prospect.

The invention belongs to the field of anticancer active natural components, and particularly relates to anticancer active glycoprotein, a preparation method and application of the anticancer active glycoprotein and an anti-female cancer medicine, and the anticancer active glycoprotein is protein chemically bonded with selenium and polysaccharide. The protein comprises a peroxidase structural domain protein, RNA dependent RNA polymerase, a nucleolus 278 pre-rRNA processed Urb / Npa2 C-terminal structural domain protein and a ribosomal protein S12; the polysaccharide chain is a sugar unit fragment with a structure shown in a formula 1; hydroxyl in the polysaccharide is connected with at least one amino acid of aspartic acid, valine, glutamic acid, arginine, lysine and serine in the protein through a hydrogen bond; the selenium bond comprises at least one of Se = O and Se-C-O. The invention provides a selenoglycoprotein component with a brand new structure, and further research shows that the selenoglycoprotein component can specifically inhibit female cancer cells and has relatively low normal cell inhibitory activity.

The invention provides a method for predicting myocarditis by using circular RNAcirc0071542 and ribosomal protein RPL13A. The method comprises the following steps: a) obtaining a biological sample of a subject; b) detecting the expression level of circACSL1 in the biological sample; c) comparing the expression level of the circACSL1 with a reference value from a healthy control; and d) when the expression level of the circACSL1 is higher than the reference value, judging that the subject has a myocarditis risk or is in a myocarditis state according to a difference value between the expression level of the circACSL1 and the reference value. The circACSL1 expression level is compared with the typical expression range of a dilated cardiomyopathy (DCM) subject to generate differential diagnosis data, and the expression difference of the marker between myocarditis and DCM can be utilized to effectively assist in clinically distinguishing the two diseases with different treatment strategies and prognosis but similar clinical manifestations.

A recombinant multi-epitope immunogenic polypeptide derived from *C. bancroftian* and its applications are disclosed. The amino acid sequence of the recombinant multi-epitope immunogenic polypeptide includes a fragment of the *Mycobacterium tuberculosis* 50S ribosomal protein L7 / L12, a cytotoxic T lymphocyte epitope, a helper T lymphocyte epitope, and a linear B cell epitope, formed by tandem linkers. The nucleotide coding sequence of the polypeptide is also disclosed. This invention further discloses a recombinant expression vector containing the nucleic acid molecule, a host cell containing the recombinant expression vector, an immunogenic composition containing the recombinant multi-epitope immunogenic polypeptide, and a method for preparing the recombinant multi-epitope immunogenic polypeptide. Immuninformatics analysis results show that the polypeptide is antigenic, non-sensitizing, and non-toxic; structural prediction, molecular docking, and computer immunosimulation results suggest its application potential as a candidate immunogenic polypeptide related to *C. bancroftian*.

The application belongs to the field of anticancer active natural ingredients, and particularly relates to an anticancer active glycoprotein, a preparation method and application thereof, and an anticancer drug for female cancer, wherein the anticancer active glycoprotein is a protein chemically bonded with selenium and polysaccharide, the protein includes a peroxidase domain protein, an RNA-dependent RNA polymerase, a nucleolar 278 pre-rRNA processing Urb / Npa2 C-terminal domain-containing protein, and a ribosomal protein S12; the polysaccharide chain is a sugar unit fragment with a structure of formula 1; the hydroxyl in the polysaccharide is connected to at least one amino acid in aspartic acid, valine, glutamic acid, arginine, lysine and serine in the protein through a hydrogen bond; and the selenium bond includes at least one of Se=O and Se-C-O. The application provides a novel structure of selenium glycoprotein ingredient, and further research shows that the ingredient can specifically inhibit female cancer cells and has a lower normal cell inhibition activity.

The application belongs to the technical field of biotechnology, and provides a Streptococcus suis type 2 (SS2) multi-epitope inhalation subunit vaccine and application thereof.Four CTL epitopes, seven HTL epitopes and six B cell epitopes are screened from the conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, and the four CTL epitopes, the seven HTL epitopes and the six B cell epitopes are fused by AAY / GPGPG / EAAAK linkers and introduced into L7 / L12 ribosomal protein as an adjuvant to construct an inhalation subunit vaccine 1022-SpaA V3.The vaccine is intranasally primed and boosted at 60 μg, can improve respiratory mucosa sIgA and serum IgG levels, activate related immune cells, and form a mucosal and systemic double immune mechanism.The survival rate of mice after SS2 multi-strain challenge is up to 100%, and the bacterial load can be reduced.The vaccine is safe and non-toxic, inhalation can save cost, and is suitable for industrial scale production.

The present invention provides a method for determining the resistance of a microorganism to a drug by detecting at least a transcript of a drug resistance gene from a microorganism in a biological sample, the method comprising the steps of: (i) lysing the cells by means of a chemical or a mechanical method, thereby obtaining a lysate and cell debris; (ii) obtaining a ribosome-antibody complex from the lysate using an antibody or a fragment thereof which binds specifically to a microorganism-ribosomal protein; (iii) purifying the mRNA associated to the ribosome-antibody complex by means of a nucleic acid extraction method; and (iv) submitting the resulting mRNA to a specific gene detection method, thereby identifying the at least one drug resistance gene transcript of the biological sample. Provided methods and kits allow determining the resistance to antibiotics of a biological sample in a rapid and reliable manner, thereby minimizing the risk of AMR and allowing the definition of the therapeutic potential of a selected antibiotic

The application provides a preparation method of 30S ribosomal protein S1 and use of the 30S ribosomal protein S1 as an antibacterial synergist, and belongs to the technical field of biological medicines. The 30S ribosomal protein S1 in the application is a bioactive protein produced by Acinetobacter bacteria, and has the effect of enhancing the antibacterial capacity of antibiotics. In the process of being combined with streptomycin sulfate, the 30S ribosomal protein S1 greatly enhances the inhibiting capacity of streptomycin sulfate on avian pathogenic E.coli without showing the effect of inhibiting bacteria itself, which lays a foundation for future practical application, and also plays a reference role for the development of new antibacterial synergists.

The invention relates to the technical field of genetic engineering, in particular to application of toxoplasma gondii coryneform protein 16 in preparation of a medicine for treating lung adenocarcinoma. The toxoplasma gondii RH strain ROP16 is used as a carrier, a prokaryotic expression system is constructed through escherichia coli, large-scale expression of ROP16 protein is achieved, the influence of exogenous fusion protein ROP16 on human lung adenocarcinoma cell proliferation, apoptosis and cell cycle is further explored, whether the ROP16 protein can inhibit lung adenocarcinoma cell malignant biology or not is ascertained, and the lung adenocarcinoma cell malignant biology can be inhibited. The medicine has the potential of being developed into an adjuvant therapy medicine for lung adenocarcinoma.

The application belongs to the technical field of genetic engineering, and particularly relates to a ribosomal protein N' mutant and application thereof. The ribosomal protein N' mutant is subjected to Y190D mutation. When the ribosomal protein N' expressed by a production strain is subjected to Y190D mutation, the production of LNT II is increased by 28.6%, the production of LNnT is increased by 50%, the production of LNT is increased by 92.3%, the production of 3'-SL is increased by 13.8%, and the production of 6'-SL is increased by 20%. It can be seen that after the 190th amino acid of PriA is changed from tyrosine to aspartic acid, the production capacity is improved. When the ribosomal protein N' mutant is applied to an Escherichia coli for producing human milk oligosaccharides, the production of human milk oligosaccharides is significantly improved.

The invention belongs to the technical field of antitumor drug research, and particularly relates to application of a reagent for detecting mitochondrial ribosomal protein MRPS30 in preparation of products for colorectal cancer diagnosis or prognosis. The amino acid sequence of the mitochondrial ribosomal protein MRPS30 is as shown in SEQ ID NO. 1. Researches show that the proliferation and invasion of colorectal cancer cells can be remarkably inhibited by knocking down the MRPS30, the expression quantity of the MRPS30 in colorectal cancer tissues is higher than that of the MRPS30 in corresponding normal tissues, and the prognosis of the colorectal cancer is poor due to high expression of the MRPS30. Therefore, siRNA aiming at MRPS30 is designed, and corresponding experiments prove that siRNA has a good tumor progress inhibition effect and is expected to be applied to development of anti-colorectal cancer drugs.